Want to see HK:2179 full AI Analyst Report?
Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$5.00
▲(19.62% Upside)
Action:Reiterated
Date:08/10/26
The score is primarily weighed down by weak financial performance—volatile revenue, sustained heavy losses, and ongoing cash burn—despite improved leverage. Technicals are neutral with only modest positive momentum, and valuation remains constrained by negative earnings and no stated dividend support.
Positive Factors
Improved leverage
A meaningful year-over-year reduction in debt-to-equity materially lowers financial risk and interest burden, improving flexibility. Durable impact: with lower leverage the company can better withstand biotech R&D cycles, access capital on firmer terms, and extend runway for clinical and commercialization milestones.
Negative Factors
Persistent cash burn
Chronic negative operating and free cash flow forces dependence on external financing, raising dilution and execution risk. Over the medium term this constrains R&D and commercialization pacing, increases refinancing exposure, and can limit the ability to capitalize on growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
A meaningful year-over-year reduction in debt-to-equity materially lowers financial risk and interest burden, improving flexibility. Durable impact: with lower leverage the company can better withstand biotech R&D cycles, access capital on firmer terms, and extend runway for clinical and commercialization milestones.
Read all positive factors
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.11B
Dividend YieldN/A
Average Volume (3M)883.00
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue Growth-82.46%
EPS Growth41.19%
CountryHK
Employees491
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.77
Shares Outstanding458,092,160
10 Day Avg. Volume550
30 Day Avg. Volume883
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A significant portio...
How the Company Makes Money
null...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.29M | 12.40M | 27.00M | 30.38M | 5.33M | 6.20M |
| Gross Profit | -47.33M | -91.46M | 15.95M | 22.34M | 5.33M | 6.20M |
| EBITDA | -357.67M | -486.44M | -523.97M | -569.87M | -847.67M | -590.00M |
| Net Income | -477.06M | -594.59M | -562.39M | -571.96M | -719.20M | -657.56M |
Balance Sheet | ||||||
| Total Assets | 1.60B | 1.76B | 1.94B | 2.19B | 2.31B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 187.51M | 351.99M | 448.31M | 837.76M | 1.33B | 1.18B |
| Total Debt | 672.99M | 638.75M | 889.10M | 650.79M | 282.63M | 76.72M |
| Total Liabilities | 1.10B | 1.06B | 1.41B | 1.12B | 656.53M | 245.92M |
| Stockholders Equity | 497.98M | 706.14M | 529.32M | 1.07B | 1.66B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | -332.78M | -601.50M | -636.66M | -862.18M | -888.04M | -710.79M |
| Operating Cash Flow | -289.02M | -502.64M | -464.82M | -638.07M | -579.54M | -472.92M |
| Investing Cash Flow | -40.16M | 35.43M | -279.04M | 9.42M | -378.43M | 68.70M |
| Financing Cash Flow | 566.24M | 499.77M | 218.06M | 275.27M | 839.44M | 1.23B |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Neutral
4.18
Price Trends
5.00
Positive
4.98
Positive
4.95
Positive
Market Momentum
<0.01
Positive
50.32
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Neutral. The current price of 4.18 is below the 20-day moving average (MA) of 5.00, below the 50-day MA of 5.00, and below the 200-day MA of 4.95, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.32 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$38.22B | 37.75 | 20.41% | ― | 32.63% | 8.87% | |
59 Neutral | HK$3.40B | 4.71 | 10.99% | ― | 1417.68% | 660.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$2.73B | 2.72 | -64.89% | ― | -99.15% | ― | |
49 Neutral | HK$2.93B | -14.80 | -26.14% | ― | -51.10% | -2384.76% | |
47 Neutral | HK$3.11B | -5.56 | -79.24% | ― | -82.46% | 41.19% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% |
* Healthcare Sector Average
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.00
-2.50
-33.33%
HK:6998
Genor Biopharma Holdings Limited
1.69
-3.12
-64.97%
HK:1875
TOT BIOPHARM International Co. Ltd.
3.83
1.43
59.38%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.66
-19.18
-52.06%
HK:2197
Clover Biopharmaceuticals Ltd.
2.19
0.04
1.63%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.55
-20.35
-23.69%
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Jiangsu Recbio Sets Board Meeting to Review 2026 Interim Results and Consider Dividend
Aug 7, 2026
Jiangsu Recbio Technology Co., Ltd., a Hong Kong–listed biopharmaceutical company incorporated in the PRC, has a board structure that includes a non-executive chairman, multiple executive and non-executive directors, and several independent ...
Jiangsu Recbio Flags Narrowed First-Half Loss as Clinical Spend Eases
Jul 31, 2026
Jiangsu Recbio Technology has warned of a continued loss for the first half of 2026, although its estimated net loss has narrowed significantly compared with a year earlier. The improvement reflects the completion of heavy clinical trial investmen...
Recbio Reports Shingles Vaccine Milestone and Delay in HPV Filing
Jul 23, 2026
Jiangsu Recbio Technology Co., Ltd., a Hong Kong-listed Chinese vaccine developer, focuses on recombinant and adjuvanted vaccines targeting shingles and HPV, using advanced biotechnological platforms in its RD and manufacturing operations. Its pip...
Recbio Shareholders Approve All Resolutions at 2025 AGM
May 28, 2026
Jiangsu Recbio Technology Co., Ltd. reported that its 2025 annual general meeting in Taizhou, Jiangsu Province, achieved a quorum with shareholders and proxies representing about 51% of issued shares. All directors attended, and the meeting was co...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.